These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
669 related articles for article (PubMed ID: 19363436)
1. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436 [TBL] [Abstract][Full Text] [Related]
2. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. Lim KH; Kim TY; Lee KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ Cancer Chemother Pharmacol; 2011 Oct; 68(4):1017-26. PubMed ID: 21327930 [TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318 [TBL] [Abstract][Full Text] [Related]
5. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399 [TBL] [Abstract][Full Text] [Related]
7. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437 [TBL] [Abstract][Full Text] [Related]
8. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161 [TBL] [Abstract][Full Text] [Related]
9. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346 [TBL] [Abstract][Full Text] [Related]
10. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ Oncology; 2012; 83(2):57-66. PubMed ID: 22760079 [TBL] [Abstract][Full Text] [Related]
11. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Oh SY; Kim HJ; Kim TH; Lee GW; Kim HG; Jeong CY; Kwon HC; Kang JH Invest New Drugs; 2010 Jun; 28(3):343-9. PubMed ID: 19444385 [TBL] [Abstract][Full Text] [Related]
12. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446 [TBL] [Abstract][Full Text] [Related]
14. Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. Unal OU; Oztop I; Unek IT; Yilmaz AU Asian Pac J Cancer Prev; 2013; 14(9):5263-7. PubMed ID: 24175811 [TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Alberts SR; Al-Khatib H; Mahoney MR; Burgart L; Cera PJ; Flynn PJ; Finch TR; Levitt R; Windschitl HE; Knost JA; Tschetter LK Cancer; 2005 Jan; 103(1):111-8. PubMed ID: 15558814 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Murad AM; Guimarães RC; Aragão BC; Rodrigues VH; Scalabrini-Neto AO; Padua CA; Moore FC Am J Clin Oncol; 2003 Apr; 26(2):151-4. PubMed ID: 12714886 [TBL] [Abstract][Full Text] [Related]
17. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099 [TBL] [Abstract][Full Text] [Related]
18. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Raderer M; Hejna MH; Valencak JB; Kornek GV; Weinländer GS; Bareck E; Lenauer J; Brodowicz T; Lang F; Scheithauer W Oncology; 1999 Apr; 56(3):177-80. PubMed ID: 10202270 [TBL] [Abstract][Full Text] [Related]
19. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Kornek GV; Schuell B; Laengle F; Gruenberger T; Penz M; Karall K; Depisch D; Lang F; Scheithauer W Ann Oncol; 2004 Mar; 15(3):478-83. PubMed ID: 14998852 [TBL] [Abstract][Full Text] [Related]
20. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]